Definium Therapeutics, Inc. (DFTX) - Net Assets
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has net assets worth $918.68 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.11 Billion) and total liabilities ($194.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Definium Therapeutics, Inc. (DFTX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $918.68 Million |
| % of Total Assets | 82.55% |
| Annual Growth Rate | 102.65% |
| 5-Year Change | 119.12% |
| 10-Year Change | 261001.2% |
| Growth Volatility | 1128.82 |
Definium Therapeutics, Inc. - Net Assets Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Definium Therapeutics, Inc. (DFTX) total market value.
Annual Net Assets for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual net assets of Definium Therapeutics, Inc. from 2015 to 2025. Also explore DFTX net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $332.33 Million | +37.64% |
| 2024-12-31 | $241.45 Million | +209.02% |
| 2023-12-31 | $78.13 Million | -48.23% |
| 2022-12-31 | $150.92 Million | -0.49% |
| 2021-12-31 | $151.66 Million | +99.91% |
| 2020-12-31 | $75.87 Million | +2670.96% |
| 2019-12-31 | $2.74 Million | -22.32% |
| 2018-12-31 | $3.52 Million | -10.70% |
| 2017-12-31 | $3.95 Million | +3001.10% |
| 2016-12-31 | $127.28K | -55.21% |
| 2015-12-31 | $284.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Definium Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58235860100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $1.08 Million | 0.33% |
| Other Components | $913.91 Million | 275.00% |
| Total Equity | $332.33 Million | 100.00% |
Definium Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Definium Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sulzer AG
SW:SUN
|
$5.02 Billion |
|
EPAM Systems Inc
NYSE:EPAM
|
$5.03 Billion |
|
UPL Limited
NSE:UPL
|
$5.03 Billion |
|
APT Medical Inc
SHG:688617
|
$5.03 Billion |
|
CHINA TOWER UNSP.ADR/100
F:2Y10
|
$5.02 Billion |
|
Zhejiang Crystal Optech Co Ltd
SHE:002273
|
$5.02 Billion |
|
Bilibili Inc
NASDAQ:BILI
|
$5.02 Billion |
|
Corporacion Financiera Alba SA
MC:ALB
|
$5.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Definium Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 241,448,000 to 332,327,000, a change of 90,879,000 (37.6%).
- Net loss of 183,793,000 reduced equity.
- New share issuances of 258,858,000 increased equity.
- Other comprehensive income increased equity by 266,000.
- Other factors increased equity by 15,548,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-183.79 Million | -55.3% |
| Share Issuances | $258.86 Million | +77.89% |
| Other Comprehensive Income | $266.00K | +0.08% |
| Other Changes | $15.55 Million | +4.68% |
| Total Change | $- | 37.64% |
Book Value vs Market Value Analysis
This analysis compares Definium Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.52x to 10.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $3.60 | $37.85 | x |
| 2016-12-31 | $1.58 | $37.85 | x |
| 2017-12-31 | $15.61 | $37.85 | x |
| 2018-12-31 | $11.28 | $37.85 | x |
| 2019-12-31 | $7.22 | $37.85 | x |
| 2020-12-31 | $4.27 | $37.85 | x |
| 2021-12-31 | $5.54 | $37.85 | x |
| 2022-12-31 | $4.89 | $37.85 | x |
| 2023-12-31 | $2.00 | $37.85 | x |
| 2024-12-31 | $0.34 | $37.85 | x |
| 2025-12-31 | $3.72 | $37.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Definium Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-55.30%) is above the historical average (-57.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -32.61% | 0.00% | 0.00x | 1.03x | $-121.07K |
| 2016 | -141.34% | 0.00% | 0.00x | 1.59x | $-192.63K |
| 2017 | -31.08% | 0.00% | 0.00x | 1.02x | $-1.62 Million |
| 2018 | -24.34% | 0.00% | 0.00x | 1.00x | $-1.21 Million |
| 2019 | -40.75% | 0.00% | 0.00x | 1.07x | $-1.39 Million |
| 2020 | -44.95% | 0.00% | 0.00x | 1.07x | $-41.69 Million |
| 2021 | -61.34% | 0.00% | 0.00x | 1.08x | $-108.20 Million |
| 2022 | -37.63% | 0.00% | 0.00x | 1.13x | $-71.89 Million |
| 2023 | -122.52% | 0.00% | 0.00x | 1.59x | $-103.55 Million |
| 2024 | -45.01% | 0.00% | 0.00x | 1.25x | $-132.82 Million |
| 2025 | -55.30% | 0.00% | 0.00x | 1.32x | $-217.03 Million |
Industry Comparison
This section compares Definium Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,571,196
- Average return on equity (ROE) among peers: -90.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $918.68 Million | -32.61% | 0.21x | $5.02 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $112.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $44.03 Million | -144.75% | 1.47x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.36 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $8.92 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $4.75 Billion |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more